The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved ... Further boosting the pipeline, ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or EoE, ...

Good morning and welcome to the Regeneron Pharmaceuticals ... primarily driven by higher Sanofi collaboration revenues reflecting the continued strong performance of Dupixent, continued growth ...

Blockbuster immunology drug Dupixent so far generates 80% of its sales in the US, and Regeneron is beginning to book a significant profit share on the drug from partner Sanofi. Proposals for ...

TARRYTOWN, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... higher profits associated with an increase in Dupixent sales. Sanofi collaboration revenue in the third quarter ...

Hence, investors should also focus on Dupixent’s performance, sales of which are recorded by Sanofi SNY. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.